Last reviewed · How we verify
Clade C gp140 plus adjuvant — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Clade C gp140 plus adjuvant (Clade C gp140 plus adjuvant) — Janssen Vaccines & Prevention B.V..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Clade C gp140 plus adjuvant TARGET | Clade C gp140 plus adjuvant | Janssen Vaccines & Prevention B.V. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Clade C gp140 plus adjuvant CI watch — RSS
- Clade C gp140 plus adjuvant CI watch — Atom
- Clade C gp140 plus adjuvant CI watch — JSON
- Clade C gp140 plus adjuvant alone — RSS
Cite this brief
Drug Landscape (2026). Clade C gp140 plus adjuvant — Competitive Intelligence Brief. https://druglandscape.com/ci/clade-c-gp140-plus-adjuvant. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing